These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 24635837)

  • 1. A meta-analysis of the hypoglycaemic risk in randomized controlled trials with sulphonylureas in patients with type 2 diabetes.
    Monami M; Dicembrini I; Kundisova L; Zannoni S; Nreu B; Mannucci E
    Diabetes Obes Metab; 2014 Sep; 16(9):833-40. PubMed ID: 24635837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis.
    Salvo F; Moore N; Arnaud M; Robinson P; Raschi E; De Ponti F; Bégaud B; Pariente A
    BMJ; 2016 May; 353():i2231. PubMed ID: 27142267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis.
    Goring S; Hawkins N; Wygant G; Roudaut M; Townsend R; Wood I; Barnett AH
    Diabetes Obes Metab; 2014 May; 16(5):433-42. PubMed ID: 24237939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoglycaemia in the over 75s: Understanding the predisposing factors in type 2 diabetes (T2DM).
    Heald AH; Anderson SG; Cortes GJ; Cholokova V; Narajos M; Khan A; Donnahey G; Livingston M
    Prim Care Diabetes; 2018 Apr; 12(2):133-138. PubMed ID: 28941578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of and risk factors for severe hypoglycaemia in treated type 2 diabetes mellitus patients in the UK--a nested case-control analysis.
    Bruderer SG; Bodmer M; Jick SS; Bader G; Schlienger RG; Meier CR
    Diabetes Obes Metab; 2014 Sep; 16(9):801-11. PubMed ID: 24612200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of hypoglycaemia in people aged ≥65 years receiving linagliptin: pooled data from 1489 individuals with type 2 diabetes mellitus.
    Nauck M; Araki A; Hehnke U; Plat A; Clark D; Khunti K
    Int J Clin Pract; 2018 Oct; 72(10):e13240. PubMed ID: 30216648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trial.
    Gallwitz B; Rosenstock J; Patel S; von Eynatten M; Hehnke U; Mehlburger L; Dugi KA; Woerle HJ
    Diabetes Obes Metab; 2015 Mar; 17(3):276-84. PubMed ID: 25425502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The benefits and risks of DPP4-inhibitors vs. sulfonylureas for patients with type 2 diabetes: accumulated evidence from randomised controlled trial.
    Zhou JB; Bai L; Wang Y; Yang JK
    Int J Clin Pract; 2016 Feb; 70(2):132-41. PubMed ID: 26709610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A deprescribing programme aimed to optimise blood glucose-lowering medication in older people with type 2 diabetes mellitus, the OMED2-study: the study protocol for a randomised controlled trial.
    Andriessen C; Blom MT; van Hoek BACE; de Boer AW; Denig P; de Wit GA; Swart K; de Rooij-Peek A; van Marum RJ; Hugtenburg JG; Slottje P; van Raalte D; van Bloemendaal L; Herings R; Nijpels G; Vos RC; Elders PJM
    Trials; 2024 Jul; 25(1):505. PubMed ID: 39049109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher incidence of severe hypoglycaemia leading to hospital admission in Type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas.
    Stahl M; Berger W
    Diabet Med; 1999 Jul; 16(7):586-90. PubMed ID: 10445835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and effectiveness of non-insulin glucose-lowering agents in the treatment of people with type 2 diabetes who observe Ramadan: a systematic review and meta-analysis.
    Gray LJ; Dales J; Brady EM; Khunti K; Hanif W; Davies MJ
    Diabetes Obes Metab; 2015 Jul; 17(7):639-48. PubMed ID: 25777247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea.
    Moses RG; Kalra S; Brook D; Sockler J; Monyak J; Visvanathan J; Montanaro M; Fisher SA
    Diabetes Obes Metab; 2014 May; 16(5):443-50. PubMed ID: 24205943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
    Gooßen K; Gräber S
    Diabetes Obes Metab; 2012 Dec; 14(12):1061-72. PubMed ID: 22519906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials.
    Monami M; Nardini C; Mannucci E
    Diabetes Obes Metab; 2014 May; 16(5):457-66. PubMed ID: 24320621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluoroquinolones and the risk of severe hypoglycaemia among sulphonylurea users: Population-based cohort study.
    Dimakos J; Cui Y; Platt RW; Renoux C; Filion KB; Douros A
    Diabetes Obes Metab; 2024 Aug; 26(8):3088-3098. PubMed ID: 38698651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Japanese adults with type 2 diabetes: A 12-month comparison by concomitant sulphonylurea and/or glinide use.
    Terauchi Y; Riddle MC; Hirose T; Koyama M; Cheng X; Takahashi Y; Bolli GB
    Diabetes Obes Metab; 2018 Nov; 20(11):2541-2550. PubMed ID: 29888454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study.
    van Dalem J; Brouwers MC; Stehouwer CD; Krings A; Leufkens HG; Driessen JH; de Vries F; Burden AM
    BMJ; 2016 Jul; 354():i3625. PubMed ID: 27413017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative studies of dipeptidyl peptidase 4 inhibitor vs sulphonylurea among Muslim Type 2 diabetes patients who fast in the month of Ramadan: A systematic review and meta-analysis.
    Loh HH; Yee A; Loh HS; Sukor N; Kamaruddin NA
    Prim Care Diabetes; 2016 Jun; 10(3):210-9. PubMed ID: 26392074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sitagliptin add-on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes.
    Harashima SI; Ogura M; Tanaka D; Fukushima T; Wang Y; Koizumi T; Aono M; Murata Y; Seike M; Inagaki N
    Int J Clin Pract; 2012 May; 66(5):465-76. PubMed ID: 22512606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.